March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
A Comparative Evaluation Of Translational Read-through Inducing Drugs For Treatment Of Ush
Author Affiliations & Notes
  • Kerstin Nagel-Wolfrum
    Cell and Matrix Biology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Tobias Goldmann
    Cell and Matrix Biology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Fabian Möller
    Cell and Matrix Biology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Nora Overlack
    Cell and Matrix Biology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Valery Belakhov
    Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa, Israel
  • Timor Baasov
    Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa, Israel
  • Uwe Wolfrum
    Cell and Matrix Biology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Footnotes
    Commercial Relationships  Kerstin Nagel-Wolfrum, None; Tobias Goldmann, None; Fabian Möller, None; Nora Overlack, None; Valery Belakhov, None; Timor Baasov, None; Uwe Wolfrum, None
  • Footnotes
    Support  Deutsche Forschungsgemeinschaft (GRK1044), European Community FP7/2009/241955 ("SYSCILIA"), FAUN-Stiftung, Nuremberg, Foundation Fighting Blindness (FFB), US-Israel Binational Science Foundation, Germ
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5576. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kerstin Nagel-Wolfrum, Tobias Goldmann, Fabian Möller, Nora Overlack, Valery Belakhov, Timor Baasov, Uwe Wolfrum; A Comparative Evaluation Of Translational Read-through Inducing Drugs For Treatment Of Ush. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5576. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Translational read-through inducing drugs (TRIDs), promote read-through of nonsense mutations, placing them in the spotlight of current gene-based therapeutic research. We compare the efficacies of different TRIDs as a treatment option for nonsense mutation-based retinal disorders, focusing on the human Usher syndrome (USH). USH is the most frequent cause of inherited combined deaf-blindness. It is clinically and genetically heterogeneous, assigned to three clinical USH types and 11 known gene loci. So far no effective treatment for the ophthalmic component of USH exists. In USH, nonsense mutations account for ~11% of all disease-causing mutations.

Methods: : We assessed retinal toxicities of TRIDs in mouse and human retinal explants by TUNEL-assays and immunofluorescence analyses applying molecular markers for retinal integrity. We generated constructs coding for disease-related nonsense mutations in USH1C and USH2A and quantified TRIDs induced read-through on the different USH causing nonsense mutations in HEK293T cells, mouse retinal explants and in vivo in mice.

Results: : In comparison with classical aminoglycoisdes (gentamicin), designer aminoglycosides and PTC124 exhibits significant better retinal biocompatibility. We observed a dose-dependent read-through of the USH nonsense mutations by TRIDs in transfected cultured cells. We demonstrate the functionality of the recovered proteins. In addition, we show TRIDs induced read-through in transfected retinal explants and in vivo in murine retinas.

Conclusions: : The high biocompatibility combined with the good read-through efficacies of TRIDs emphasizes the potential of designer aminoglycosides and PTC124 in treating nonsense mutation-based retinal disorders, in particular for USH.

Keywords: gene transfer/gene therapy • drug toxicity/drug effects • retinal degenerations: hereditary 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×